395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells

Ítems similars

• 1139 Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models
  per: Adam Parks, et al.
  Publicat: (2023-11-01)
• 395 Enhancement of bispecific T cell engagers (bispecific TCE) killing potency in AML with the neximmune artificial immune modulation (AIM™) adoptive cell therapy (ACT) T cells
  per: Rui Wang, et al.
  Publicat: (2023-11-01)
• Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness
  per: Manpreet Bariana, et al.
  Publicat: (2025-06-01)
• Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
  per: Malcolm K Brenner, et al.
  Publicat: (2023-04-01)
• 1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
  per: Scott Garforth, et al.
  Publicat: (2023-11-01)